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T
he rehabilitation of substance-abusing criminal
offenders is an urgent issue for public health and
public safety. In addition, improving treatment for these
individuals could be a key to raising the overall success
rates in the Nation’s drug abuse treatment system. In
some States, as many as two-thirds of those who enroll
in community treatment programs do so under judicial
mandate (see “Drug Abuse Treatment Beyond Prison
Walls,” page 24). Yet, recent meta-analyses suggest that
substance-abusing offenders benefit less from interven-
tions to reduce recidivism or drug abuse than do sub-
stance-abusing nonoffenders or offenders who are not
involved with drugs: The findings showed smaller inter-
vention effects in study populations consisting exclu-
sively of substance-abusing offenders than in general
substance abuse or offender populations (see “Interven-
tions to Promote Successful Re-Entry Among Drug-
Abusing Parolees,” page 6).
To meet the challenge and gain the benefits of
improving care for substance-abusing offenders, NIDA
launched the Criminal Justice–Drug Abuse Treatment
Studies (CJ-DATS) project (www.cjdats.org) in 2002. In
the project’s first 6 years, CJ-DATS researchers have con-
ducted large-scale surveys of treatment availability and
effectiveness, setting a baseline for measuring improve-
ments; developed specialized screening and assess-
ment batteries for drug-abusing offenders; and gener-
ated and tested strategies to help parolees re-engage
with their communities. A second phase of the CJ-DATS
project, now under way, addresses implementation
issues, including policies and practices to integrate jus-
tice and treatment systems and practices.
In 2006, NIDA published Principles of Drug Abuse
Treatment for Criminal Justice Populations, codifying the
lessons learned from CJ-DATS and other research
(drugabuse.gov/PODAT_CJ/principles). The response to
the booklet makes clear that the sense of urgency on
this issue is widespread; it has become one of the most
requested single publications in NIDA’s history.
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